To identify potential LSD1 inhibitor (LSD1i) combination therapy partners, we performed an LSD1i “synergy screen.” We used the ER-Hoxb8 differentiation arrest model14, as it provides a genetically-defined, primary cell context that has been successfully used for prior AML screens15. Here, HOXB8 is linked to acute myeloid leukemia.